We investigated the therapeutic effect of the novel selective HDAC6 inhibitor, CKD-L, and compared its effect to those of the pan HDAC inhibitor, ITF 2357, and the selective HDAC6 inhibitor, Tubastatin A, in CIA, PBMC, and Treg cells from patients with RA. Here, HDAC9 is linked to rheumatoid arthritis.